Roche announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. This decision comes just hours after the recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency.
- Read more about Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/actemra-roactemra-approved-by-the-european-commission-to-treat-patients-with-severe-covid-19
No comments:
Post a Comment